Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Feb 3, 2023

Provention Bio Announces the Grant of Inducement Awards
- Photos 1
Feb 2, 2023

Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
Jan 25, 2023

NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
Jan 25, 2023

FDA approves expanded label of Enjaymo® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease
Jan 18, 2023

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Jan 17, 2023

FDA approves Adacel® for immunization during pregnancy to help protect young infants against pertussis
Jan 6, 2023

Provention Bio Announces the Grant of Inducement Awards
Jan 5, 2023

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
Dec 21, 2022

Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
Dec 2, 2022

Provention Bio Announces the Grant of Inducement Awards

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.